^
Association details:
| Biomarker: | SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Larotrectinib in TRK fusion-positive, metastatic non-small cell lung cancer (NSCLC) after treatment with entrectinib in a patient with a history of coronary artery disease
Published date:
04/06/2022
Excerpt:
Preliminary results on tissue biopsy were negative for alterations in EGFR, ALK, and ROS1, but programmed dealth-ligand 1 (PD-L1) expression was high; while SQSTM1-NTRK1, PIK3CA E545K, and TP53 L145R were detected on liquid biopsy...the patient was amenable to trying the other NTRK inhibitor, larotrectinib, which he tolerated much better with limited toxicities....he continues to experience a response to treatment with limited side effects.
DOI:
https://doi.org/10.1016/j.cpccr.2022.100158
